Glaxosmithkline Share News (GSK)
GSK Share
GSK Share
GSK Share
GSK Share
GSK
GSK Share
GSK Level 2
GSK Live
GSK Broker
GSK Directors
GSK Financial
GSK
GSK Short
GSK
Last checked at -
LONDON (Alliance News) - GlaxoSmithKline PLC Wednesday said it had withdrawn its marketing authorisation application for the combined use of Meikinist and Tafinlar for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation in Europe. This was as a result of the Commi
Read more
Complaints about insufficient information has led GlaxoSmithKline to temporarily withdraw a European regulatory application for the combined use of two drugs to treat certain cancers. The FTSE 100 company had applied to the European Medicines Agency (EMA) to gain approval to market its trametinib/
Read more
* Final Phase III results due by late September * Sanofi hopes to deliver first doses in late 2015 * Sanofi has spent over 1.3 bln euros on project * Sales could top 1 bln euros but project is risky -analysts By Natalie Huet and Noëlle Mennella NEUVILLE-SUR-SAONE, F
Read moreLAGOS, March 25 (Reuters) - The Nigerian unit of British drugmaker GlaxoSmithKline on Tuesday reported 2013 pretax profit up 3.4 percent to 4.31 billion naira ($26 million), from 4.17 billion naira the previous year. Turnover grew 15.3 percent to 29.18 billion naira during the period, comp
Read moreHealthcare group Bayer falls by more than 2 percent in early session trading, impacting rival companies such as GlaxoSmithKline and weighing on Germany's DAX index, after Bayer is dealt a blow by Britain's healthcare cost agency. Britain's healthcare cost agency recommends against using Bay
Read moreLONDON, March 21 (Reuters) - European regulators said on Friday they had recommended approval of new pills for hepatitis C and diabetes from Johnson & Johnson and Eli Lilly , respectively, and an injectable drug for ulcerative colitis from Takeda. Recommendations for marketing approval by t
Read moreLONDON (Alliance News) - UK equities are attempting to rebalance today in the wake of the tax and regulatory changes unveiled in Wednesday's government budget.
Life insurance companies have continued to take a battering during morning trading, following the announcement by Chancello
Investec has raised its rating for UK banking group Royal Bank of Scotland from 'sell' to 'hold' following the recent slump in its share price, but continues to recommend investors to avoid the stock. With the stock now trading at just 0.8 times tangible net asset value (tNAV), compared with a then
Read moreLONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.
-------
FTSE 100 - WINNERS
Next, up 1.9%. The homeware and clothing retailer reported higher profi
LONDON (Alliance News) - The following is a summary of top news stories Thursday.
----------
COMPANIES
----------
Next PLC reported higher profits and revenues for the financial year ended January 2014 driven by its online business, raised
Panmure Gordon has retained a 'hold' recommendation on shares of GlaxoSmithKline after the pharmaceuticals group reported "another disappointment" for its therapeutic cancer vaccine, MAGE-A3. Analysis of a phase III trial of its MAGE-A3 cancer immunotherapeutic in non-small cell lung cancer (NSCLC)
Read more* MAGE-A3 fails to hit goal in Phase III lung cancer trial * Setback follows disappointing 2013 results in melanoma * GSK hopes to find patient sub-set in which vaccine works * Shares fall 2 percent (Adds analyst comments, latest shares, further details) By Ben Hirschler
Read moreLONDON (Alliance News) - Shares have opened lower Thursday, as markets around the world react to Fed Chair Janet Yellen's hint of an earlier-than-expected rise in US interest rates. The CEO of handbag firm Mulberry has stepped down after only two years in the job.
LONDON (Alliance News) - GlaxoSmithKline PLC Thursday said that a late stage trial of its MAGE-A3 cancer immunotherapeutic for patients with non-small-cell lung cancer did not meet two of its co-primary endpoints, as it failed to extend disease-free survival compared to a placebo. It did no
Read morePharmaceuticals group GlaxoSmithKline has revealed that a clinical trial for its lung cancer treatment failed to meet its main objectives. Analysis of the MAGRIT placebo-controlled trial, a phase III trial of its MAGE-A3 cancer immunotherapeutic in non-small cell lung cancer (NSCLC) patients, showe
Read more
Last checked at